Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
Abstract Background Choosing a safe disease modifying therapy during the COVID-19 pandemic is challenging. This case series study was conducted to determine the incidence rate and the course of Covid-19 infection in MS/NMOSD patients treated with Rituximab. Methods In this study, we designed a web-b...
Main Authors: | Sara Esmaeili, Mohammad Hossein Abbasi, Meysam Abolmaali, Mohammad Mojtahed, Seyedeh Niloufar Rafiei Alavi, Sevim Soleimani, Mahisa Mokhtari, Jaber Hatam, Samaneh Tanhapour Khotbehsara, Mohammad Reza Motamed, Mohammad Taghi Joghataei, Zahra Mirzaasgari, Mehdi Moghaddasi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-021-02218-4 |
Similar Items
-
Pediatric Neuromyelitis Optica Spectrum Disorders: Three Case Reports and Review of Literature
by: Seyed Mohammad Baghbanian, et al.
Published: (2020-04-01) -
بررسی سطح سرمی OX40 در بیماران مبتلا به نورومیلیت اپتیکا در مقایسه با افراد سالم
by: Paria Alidadiani, et al.
Published: (2016-08-01) -
Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients
by: Alidadiani Parya, et al.
Published: (2019-04-01) -
Seroprevalence of Neuromyelitis Optica-IgG of Childhood Compared to Adults
by: J Gordon Millichap
Published: (2008-02-01) -
Plasmapheresis for Neuromyelitis Optica: A Review from the Transfusion Medicine Specialist’s Perspective
by: Akshay Batra, et al.
Published: (2018-08-01)